New RE-VERSE AD™ analyses provide additional insights on impact of Praxbind® (idarucizumab

INGELHEIM,Germany--(BUSINESSWIRE)-- BoehringerIngelheimannouncedresultsfromtwosub-analysesofthephaseIIIRE-VERSEAD™study.1,2 Thesub-analysesevaluatedthesafetyandefficacy...

--- 引用來源:https://contentparty.org/r/7ff70e868b267c7f6be52149d19e83fa 內容如有不適當或有引用爭議,請通知客服中心

繼續閱讀文章
Facebook留言板
您可能有興趣
客服信箱